Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
20-23 October, 2024
Not Confirmed
Not Confirmed
21-24 October, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
20-23 October, 2024
Industry Trade Show
Not Confirmed
21-24 October, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-have-built-considerable-expertise-in-glp-1-drug-development-through-our-oral-peptide-programs
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/us-europe-turn-to-advanced-manufacturing-stockpiling-to-strengthen-drug-supply-chains
23 Aug 2024
// BIOSPACE
https://www.biospace.com/business/novartis-versant-launch-rna-kidney-medicines-focused-borealis
11 Aug 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/08/11/2723695/0/en/Novartis-Completes-Acquisition-of-Chinook-Therapeutics.html
28 Jul 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/07/28/2713095/35377/en/Chinook-Therapeutics-Announces-First-Patient-Enrolled-in-Pivotal-Phase-3-BEYOND-Study-of-Zigakibart-BION-1301-for-Patients-with-IgA-Nephropathy.html
17 Jun 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/06/17/2689976/35377/en/Chinook-Therapeutics-Presents-Data-from-CHK-336-Phase-1-Trial-in-Healthy-Volunteers-and-New-Insights-into-the-Role-of-Failed-Repair-in-Chronic-Kidney-Disease-at-the-60th-European-R.html
12 Jun 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/06/12/2686669/35377/en/Chinook-Therapeutics-to-Present-Updated-Data-from-Zigakibart-BION-1301-Phase-1-2-Trial-in-Patients-with-IgA-Nephropathy-IgAN-at-the-60th-European-Renal-Association-ERA-Congress.html
12 Jun 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/06/12/2685935/35377/en/Chinook-Therapeutics-Enters-into-Agreement-to-be-Acquired-by-Novartis-AG.html
Details:
Through the acquisition, Novartis expands its portfolio with chinook's renal pipeline having 2 assets, CHK-01 (atrasentan hydrochloride), an oral endothelin A receptor antagonist and BION-1301 (zigakibart), an anti-APRIL monoclonal antibody, for Immunoglobulin A Nephropathy.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Brand Name: CHK-01
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Novartis Pharmaceuticals Corporation
Deal Size: $3,500.0 million Upfront Cash: $3,500.0 million
Deal Type: Acquisition August 11, 2023
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation
Deal Size : $3,500.0 million
Deal Type : Acquisition
Novartis Completes Acquisition of Chinook Therapeutics
Details : Through the acquisition, Novartis expands its portfolio with chinook's renal pipeline having 2 assets, CHK-01 (atrasentan hydrochloride), an oral endothelin A receptor antagonist and BION-1301 (zigakibart), an anti-APRIL monoclonal antibody, for Immunogl...
Brand Name : CHK-01
Molecule Type : Small molecule
Upfront Cash : $3,500.0 million
August 11, 2023
Details:
BION-1301 (zigakibart) is a novel anti-APRIL monoclonal antibody with a potentially disease-modifying approach to treating IgA nephropathy by depleting Gd-IgA1, the pathogenic IgA variant, and reducing proteinuria.
Lead Product(s): Zigakibart
Therapeutic Area: Nephrology Brand Name: BION-1301
Study Phase: Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2023
Lead Product(s) : Zigakibart
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BION-1301 (zigakibart) is a novel anti-APRIL monoclonal antibody with a potentially disease-modifying approach to treating IgA nephropathy by depleting Gd-IgA1, the pathogenic IgA variant, and reducing proteinuria.
Brand Name : BION-1301
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 28, 2023
Details:
Through the acquisition, Novartis expands its portfolio with chinook's renal pipeline having 2 assets, CHK-01 (atrasentan hydrochloride), an oral endothelin A receptor antagonist and BION-1301 (zigakibart), an anti-APRIL monoclonal antibody, for Immunoglobulin A Nephropathy.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Brand Name: CHK-01
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Novartis Pharmaceuticals Corporation
Deal Size: $3,500.0 million Upfront Cash: $3,500.0 million
Deal Type: Acquisition June 12, 2023
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation
Deal Size : $3,500.0 million
Deal Type : Acquisition
Details : Through the acquisition, Novartis expands its portfolio with chinook's renal pipeline having 2 assets, CHK-01 (atrasentan hydrochloride), an oral endothelin A receptor antagonist and BION-1301 (zigakibart), an anti-APRIL monoclonal antibody, for Immunogl...
Brand Name : CHK-01
Molecule Type : Small molecule
Upfront Cash : $3,500.0 million
June 12, 2023
Details:
The companies will leverage Chinook’s precision medicine approach and expertise in nephrology and Ionis’ expertise in RNA-targeted therapeutics for discovery, development and commercialization of an antisense oligonucleotide therapy for a rare, severe chronic kidney disease.
Lead Product(s): Antisense Oligonucleotide-based Therapy
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Large molecule
Recipient: Ionis Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 16, 2023
Lead Product(s) : Antisense Oligonucleotide-based Therapy
Therapeutic Area : Nephrology
Highest Development Status : Discovery
Recipient : Ionis Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The companies will leverage Chinook’s precision medicine approach and expertise in nephrology and Ionis’ expertise in RNA-targeted therapeutics for discovery, development and commercialization of an antisense oligonucleotide therapy for a rare, sever...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 16, 2023
Details:
CHK-336 is an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias. It is being evaluated in a phase 1 clinical trial in healthy volunteers.
Lead Product(s): CHK-336
Therapeutic Area: Genetic Disease Brand Name: CHK-336
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2023
Lead Product(s) : CHK-336
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CHK-336 is an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias. It is being evaluated in a phase 1 clinical trial in healthy volunteers.
Brand Name : CHK-336
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 11, 2023
Details:
Atrasentan (CHK-01), is a potent and selective endothelin A receptor antagonist that has the potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserve kidney function.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Brand Name: CHK-01
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Atrasentan (CHK-01), is a potent and selective endothelin A receptor antagonist that has the potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserv...
Brand Name : CHK-01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 03, 2022
Details:
BION-1301 is a humanized IgG4 monoclonal antibody that blocks APRIL, a TNF-family cytokine believed to be implicated in IgAN and other indications, from binding to its receptors.
Lead Product(s): BION-1301
Therapeutic Area: Nephrology Brand Name: BION-1301
Study Phase: Phase I/ Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2022
Lead Product(s) : BION-1301
Therapeutic Area : Nephrology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BION-1301 is a humanized IgG4 monoclonal antibody that blocks APRIL, a TNF-family cytokine believed to be implicated in IgAN and other indications, from binding to its receptors.
Brand Name : BION-1301
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 05, 2022
Details:
Chinook intends to use the net proceeds from this offering to continue its phase 3 ALIGN and phase 2 AFFINITY trials of atrasentan, fund a phase 3 clinical trial of BION-1301, continue development of CHK-336 and prepare for the potential commercial launch of atrasentan.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Brand Name: CHK-01
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: SVB Securities
Deal Size: $105.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 25, 2022
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : SVB Securities
Deal Size : $105.0 million
Deal Type : Public Offering
Chinook Therapeutics Announces Pricing of a $105 Million Public Offering
Details : Chinook intends to use the net proceeds from this offering to continue its phase 3 ALIGN and phase 2 AFFINITY trials of atrasentan, fund a phase 3 clinical trial of BION-1301, continue development of CHK-336 and prepare for the potential commercial launc...
Brand Name : CHK-01
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 25, 2022
Details:
CHK-01 (atrasentan) is a potent and selective inhibitor of the endothelin A receptor that has potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preserve kidney function.
Lead Product(s): Atrasentan
Therapeutic Area: Nephrology Brand Name: CHK-01
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2022
Lead Product(s) : Atrasentan
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CHK-01 (atrasentan) is a potent and selective inhibitor of the endothelin A receptor that has potential to provide benefit in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti-fibrotic effects to preser...
Brand Name : CHK-01
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 20, 2022
Details:
BION-1301 is a novel anti-APRIL monoclonal antibody currently in phase 1/2 clinical development for patients with IgAN. Blocking APRIL is a potentially disease-modifying approach to treating IgAN by reducing circulating levels of galactose-deficient IgA1 (Gd-IgA1).
Lead Product(s): BION-1301
Therapeutic Area: Nephrology Brand Name: BION-1301
Study Phase: Phase I/ Phase IIProduct Type: Large molecule
Sponsor: Evotec
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Lead Product(s) : BION-1301
Therapeutic Area : Nephrology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Evotec
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : BION-1301 is a novel anti-APRIL monoclonal antibody currently in phase 1/2 clinical development for patients with IgAN. Blocking APRIL is a potentially disease-modifying approach to treating IgAN by reducing circulating levels of galactose-deficient IgA1...
Brand Name : BION-1301
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 19, 2022
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?